Jhalak Dholakia, MD, Spotlights Ongoing Trial of Neoadjuvant Mirvetuximab Soravtansine in FRα-High Ovarian Cancer


An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.

In an interview with CancerNetwork®, Jhalak Dholakia, MD, a fellow at the University of Alabama, discussed an ongoing phase 2 study (NCT04606914) of carboplatin and mirvetuximab soravtansine (IMGN853) as a neoadjuvant treatment for folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer, during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.

The ongoing trial builds on what is already known about mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high expression of folate receptor–alpha (FRα) from the phase 3 SORAYA trial (NCT04296890), the results of which were also reported at the meeting.


The idea was to build off of the understanding that we had of mirvetuximab soravtansine activity in the platinum-resistant setting with SORAYA and other studies that are in progress. [We wanted to see] if we could pull that to the neoadjuvant setting as a targeted therapy for treatment of our patients.

We are screening patients who are appropriate for neoadjuvant chemotherapy for our ovarian cancer setting. If their tissue biopsy is folate receptor α positive, then they would be eligible. It is a phase 2 single-arm study, so [we are] limited in our number, but are trying to really get care to the patients who would most benefit from it.

It’s really exciting that we could use targeted therapy in the neoadjuvant setting. This is a new exciting place that we’re going in gynecologic oncology and in ovarian cancer. I could very conceivably see this being used for other targeted therapies or other agents in order to do the most we can up front with the most information we have for our patients.


Dholakia J. Single-arm phase II trial of carboplatin and mirvetuximab soravtansine as neoadjuvant chemotherapy (NACT) for advanced-stage ovarian, fallopian tube or primary peritoneal cancer (EOC) who are folate receptor a positive (NCT04606914). Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.

Related Videos
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content